Melanoma antigen peptide analogues
US7605227B2 · kind B2 · utility
4Cited by
19References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2006 |
| Grant date | Oct 20, 2009 |
| Priority date | — |
| Expiry date | Aug 20, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/645
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.